100% Overall response rate (ORR) in triple combo study with azacitidine and venetoclax in newly diagnosed AML patients 80% CR and 90% Composite Complete Remissions (CCR); median OS not reached after 9 ...
-- Treatment with both combination regimens demonstrates synergistic anti-tumor activity, supporting planned combination strategy for EO-3021 in patients with gastric or gastroesophageal junction (GEJ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback